The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 13, 2019
Filed:
Jun. 06, 2016
Applicant:
Singapore Health Services Pte Ltd, Singapore, SG;
Inventors:
Assignee:
SINGAPORE HEALTH SERVICES PTE LTD, Singapore, SG;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); C12Q 1/6886 (2018.01); A61K 31/519 (2006.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01); A61K 31/277 (2006.01); A61K 31/165 (2006.01); A01K 67/027 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A01K 67/0275 (2013.01); A61K 31/165 (2013.01); A61K 31/277 (2013.01); A61K 31/519 (2013.01); G01N 33/5011 (2013.01); G01N 33/57407 (2013.01); G01N 33/57426 (2013.01); A01K 2267/0331 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/912 (2013.01); G01N 2333/91215 (2013.01); G01N 2800/50 (2013.01);
Abstract
Natural-KilleifT-Cell Lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy. The invention relates to a method for predicting Natural Killer T-cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject comprising testing for JAK mutations. The invention also relates to a method of screening for candidate agents capable of treating NKTCL using a cell line comprising at least one JAK mutation. The invention includes an NKTCL animal model comprising at least one JAK mutation. The invention also includes JAK inhibitors for treating NKTCL.